This week Jamilee interviews Robin Farmanfarmaian. She is a professional speaker and entrepreneur, author of “The Patient as CEO” and “The Thought Leader Formula”.

Robin is the CEO and Co-founder of ArO.

From Jamilee’s podcast site:

On today’s episode of “In a Click” I talk to Robin Farmanfarmaian about how new technologies can heal & prevent medical disorders and diseases. I feel so much more knowledgeable now about the future of my health care, and think it’s important that you do too.
Enjoy! 

About Jamilee Baroud

Jamilee is a PhD candidate in the Faculty of Education at the University of Ottawa.

She has a M.Ed. with a Specialization in Women’s Studies from Lakehead University. She coordinates the Critical Research Collective/Collectif de recherche critique (CRC), a research-based discussion group comprised of professors and graduate students in the Faculty of Education.

Jamilee conducts workshops for in-service teachers, teacher candidates, and youth from marginalized communities on critical digital literacies, and for teacher candidates on citizen science education. She also works with colleagues to develop primers, discussion guides, and teaching resources.

Image Credit:  Alias Creative/ Amanda Scott

News This Week

Our books now available worldwide!

Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]

GHCE Concept

From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]

Healthcare Headlines: Challenges and Advances in 2026

Health-related updates reveal financial adjustments by Universal Health Services due to Medicaid reimbursement uncertainties, significant pollution-linked health concerns from French-British oil firm Perenco in Congo, drug trial setbacks, potential restructuring at major medical firms, [...]